Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion

ROS1-rearranged patients account for 1-2% of non-small cell lung cancer (NSCLC) cases. Approximately 10 fusion partners have been discovered, while clinical practice is actively generating knowledge of new ones and their therapeutic responses. Herein, we report a patient with stage IV NSCLC that har...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Shuli, Hu, Mangsha, Yang, Yan, Huang, Xiaojie, Li, Baizhou, Ding, Liren, Wang, Pingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096128/
https://www.ncbi.nlm.nih.gov/pubmed/35574423
http://dx.doi.org/10.3389/fonc.2022.862008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096128/
https://www.ncbi.nlm.nih.gov/pubmed/35574423
http://dx.doi.org/10.3389/fonc.2022.862008

Ejemplares similares